The androgen receptor in prostate cancer

被引:86
作者
Trapman, J [1 ]
Brinkmann, AO [1 ]
机构
[1] ERASMUS UNIV ROTTERDAM, DEPT ENDOCRINOL & REPROD, NL-3000 DR ROTTERDAM, NETHERLANDS
关键词
prostate cancer; androgen receptor; mutation; structure; function;
D O I
10.1016/S0344-0338(96)80097-5
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The androgen receptor is a member of the family of nuclear receptors. In its activated form as an androgen receptor ligand complex (the ligand can either be testosterone or 5 alpha-dihydrotestosterone), the androgen receptor is able to regulate a specific expression of target genes. The androgen receptor is expressed at high levels in male reproductive tissues. Mutations in the androgen receptor gene are the molecular cause of the androgen insensitivity syndrome, which is characterized by an abcrrant male or an apparently female phenotype. Expansion of a CAG-repeat, encoding a polymorphic glutamine stretch is the cause of a rare motor neuron disease (Kennedy's disease). Hormonal therapy is the treatment of choice for metastatic prostate cancer. Hormone refractory prostate tumors in general still express androgen receptor in a proportion of the late stage prostrate tumors, somatic mutations in the androgen receptor gene have been described. Mutations can result in diminished ligand specificity of the androgen receptor. Furthermore, it has been hypothesized that ligand independent mechanisms can also be involved in androgen receptor activation.
引用
收藏
页码:752 / 760
页数:9
相关论文
共 83 条
[61]  
SADI MV, 1993, CANCER, V71, P2574, DOI 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO
[62]  
2-1
[63]  
SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO
[64]  
2-S
[65]   SURPRISING ACTIVITY OF FLUTAMIDE WITHDRAWAL, WHEN COMBINED WITH AMINOGLUTETHIMIDE, IN TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER [J].
SARTOR, O ;
COOPER, M ;
WEINBERGER, M ;
HEADLEE, D ;
THIBAULT, A ;
TOMPKINS, A ;
STEINBERG, S ;
FIGG, WD ;
LINEHAN, WM ;
MYERS, CE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (03) :222-227
[66]   FLUTAMIDE WITHDRAWAL SYNDROME - ITS IMPACT ON CLINICAL-TRIALS IN HORMONE-REFRACTORY PROSTATE-CANCER [J].
SCHER, HI ;
KELLY, WK .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1566-1572
[67]   REGULATION OF GROWTH AND EPIDERMAL GROWTH-FACTOR RECEPTOR LEVELS OF LNCAP PROSTATE TUMOR-CELLS BY DIFFERENT STEROIDS [J].
SCHUURMANS, ALG ;
BOLT, J ;
VOORHORST, MM ;
BLANKENSTEIN, RA ;
MULDER, E .
INTERNATIONAL JOURNAL OF CANCER, 1988, 42 (06) :917-922
[68]   AUTORADIOGRAPHIC LOCALIZATION OF ANDROGEN BINDING IN THE DEVELOPING MOUSE PROSTATE [J].
SHANNON, JM ;
CUNHA, GR .
PROSTATE, 1983, 4 (04) :367-373
[69]  
SIMENTAL JA, 1991, J BIOL CHEM, V266, P510
[70]   ANDROGEN RECEPTOR GENE-MUTATIONS IN HUMAN PROSTATE-CANCER [J].
SUZUKI, H ;
SATO, N ;
WATABE, Y ;
MASAI, M ;
SEINO, S ;
SHIMAZAKI, J .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1993, 46 (06) :759-765